Juan Badimon

Professor Medicine/Cardiology

Icahn School of Medicine at Mount Sinai

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Juan Badimon is a Professor of Medicine/Cardiology at the Icahn School of Medicine at Mount Sinai in the United States. His research interests include the role of sodium-glucose cotransporter-2 inhibitors in cardio-oncology, triglyceride reduction approaches, and the impact of gender on myocardial infarction treatment outcomes. He has published recent articles examining the therapeutic potential of SGLT2 inhibitors and their effects on heart failure and renal protection.

Articles (13)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2020

Collaborators (2)

Carlos Garcia Santos-Gallego

Mount Sinai Hospital

UNITED STATES

View details

Vanessa Roldan

Associated Professor Hematology

Universidad de Murcia Facultad de Medicina

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Juan Badimon

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care?

Sotagliflozin: Two Birds with One Stone?

Men are from mars, but women are not from venus: The benefits of SGLT2 inhibitors after myocardial infarction are independent of gender

Does One Size Fits All?

New approaches to triglyceride reduction: Is there any hope left?

Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors

Uncovering the Role of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction

Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease

Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection

SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism

Per‐Protocol Versus Intention‐to‐Treat in Clinical Trials: The Example of GLOBAL‐LEADERS Trial

Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.

Collaborators (2)

Carlos Garcia Santos-Gallego

Vanessa Roldan

Make your next move.